• Contact Us
  • twitter
  • facebook
  • linkedin
  • About Us
    • Overview
    • Leadership Team
    • Board of Directors
  • Our Science
    • Overview
    • Neuromodulation: CA8 Platform
    • Revolutionizing Gene Therapy
    • Chronic Pain Treatment Innovation
    • Publications
    • Collaborators & Patents
  • Our Pipeline
    • Overview
    • ADB-101 Erythromelalgia
    • ADB-102 OA Knee Pain
    • ADB-103 OA Hip Pain
    • ADB-104 Epilepsy
    • ADB-105 Hearing Loss
    • ADB-106 Ophthalmology
  • The Pain Problem
    • Chronic Pain
    • Opioid Crisis
  • Partnering
  • News & Events
    • Press Releases
    • Events
    • Alerts

Adolore Biotherapeutics Strengthens Management Team and Board of Directors with the Appointments of Roelof Rongen, MSE, MBA and Mark C. Rogers, MD, MBA

by AdoloreJTC24 | Jan 17, 2023 | Press Releases

Mr. Rongen appointed as CEO and member of the Board bringing 30 years of executive leadership experience and expertise across a number of therapeutic areasBolstered expertise on Board of Directors with addition of Dr. Rogers who brings significant leadership and...

Adolore BioTherapeutics Invited to Present at the 16th Annual Pain Therapeutics Summit

by AdoloreJTC24 | Nov 14, 2022 | Press Releases

Company to discuss its next generation, disease-modifying, non-opioid analgesic gene therapy in development for the treatment of chronic painDELRAY BEACH, FL / November 14, 2022 / Adolore BioTherapeutics, Inc. (“Adolore” or the “Company”), a...
Next Entries »

Recent Posts

  • Adolore BioTherapeutics Announces FDA Orphan Drug Designation for its Kv7-activating rdHSV-CA8* Therapy in the Treatment of Erythromelalgia
  • Dr. Roy Levitt, Executive Chairman of Adolore BioTherapeutics, Presented at the Next Generation Gene Therapy Vectors Summit
  • Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
  • Adolore BioTherapeutics to Present at Festival of Biologics USA 2025
  • Adolore BioTherapeutics to Present CA8* Neuromodulating Gene Therapy at the 2025 NANS Annual Meeting

Recent Comments

No comments to show.
Delray Beach, FL 33446, USA
Sign Up!
Stay up to date and get
notifications via email
when we post updates

Company Contact:

info@adolore.com

© 2026  Adolore BioTherapeutics.  All rights reserved.             Privacy Policy               Terms  and Conditions